| (1) |
Perros P, Crombie AL, Kendall-Taylor P. Natural history
of thyroid associated ophthalmopathy. Clin Endocrinol 1995; 42: 45-50. |
| (2) |
Weetman AP, Poole J. Failure to find an association
of blood group P1 with thyroid-associated ophthalmopathy. Clin Endocrinol
1992; 37: 423-5. |
| (3) |
Prummel MF, Wiersinga WM. Smoking and risk of Graves'
disease. JAMA 1993; 269: 479-82. |
| (4) |
Metcalfe RA, Weetman AP. Stimulation of extraocular
muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated
ophthalmopathy. Clin Endocrinol 1994; 40: 67-72. |
| (5) |
Hofbauer LC, Muhlberg T, Konig A, Heufelder G, Schworm
HD, Heufelder AE. Soluble interleukin-1 receptor antagonist serum levels
in smokers and nonsmokers with Graves' ophthalmopathy undergoing orbital
radiotherapy. J Clin Endocrinol Metab 1997; 82: 2244-57. |
| (6) |
Prummel MF, van Pareren Y, Bakker O, Wiersinga WM. Anti-heat
shock protein (hsp)72 antibodies are present in patients with Graves' disease
(GD) and in smoking control subjects. Clin Exp Immunol 1997; 110: 292-5. |
| (7) |
Bartalena L, Marcocci C, Bogazzi F, et al. Relation
between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
N Engl J Med 1998; 338: 73-8. |
| (8) |
Tallstedt L, Lundell G, Torring O, et al. Occurrence
of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl
J Med 1992; 326: 1733-8. |
| (9) |
Kung AW, Yau CC, Cheng A. The incidence of ophthalmopathy
after radioiodine therapy for Graves' disease: prognostic factors and the
role of methimazole. J Clin Endocrinol Metab 1994; 79: 542-6. |
| (10) |
Tallstedt L, Lundell G, Blomgren H, Bring J. Does early
administration of thyroxine reduce the development of Graves' ophthalmopathy
after radioiodine treatment? Eur J Endocrinol 1994; 130: 494-7. |